|
PATENT DUCTUS ARTERIOSUS 3
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
Mutations in the Histone Modifier PRDM6 Are Associated with Isolated Nonsyndromic Patent Ductus Arteriosus.
|
27181681 |
2016 |
|
PATENT DUCTUS ARTERIOSUS 3
|
0.600 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
PATENT DUCTUS ARTERIOSUS 3
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Patent ductus arteriosus
|
0.410 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Patent ductus arteriosus
|
0.410 |
GeneticVariation
|
disease |
BEFREE |
Our findings identify PRDM6 mutations as underlying genetic causes of nonsyndromic isolated PDA in humans and implicates the wild-type protein in epigenetic regulation of ductus remodeling.
|
27181681 |
2016 |
|
Patent ductus arteriosus
|
0.410 |
Biomarker
|
disease |
HPO |
|
|
|
|
Patent Ductus Arteriosus Familial
|
0.300 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Alopecia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic prediction of male pattern baldness.
|
28196072 |
2017 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Association analysis identifies 65 new breast cancer risk loci.
|
29059683 |
2017 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Identification of 64 Novel Genetic Loci Provides an Expanded View on the Genetic Architecture of Coronary Artery Disease.
|
29212778 |
2018 |
|
Hepatitis B
|
0.030 |
Biomarker
|
disease |
BEFREE |
Sensitivity of the recently licensed Abbott PRISM hepatitis B surface antigen (HBsAg) CLIA and minipool (MP) HBV NAT has been described as comparable and thus the need for HBV NAT has not been compelling.
|
18422847 |
2008 |
|
Hepatitis B
|
0.030 |
Biomarker
|
disease |
BEFREE |
The mean IWPs were Tigris HIV RNA 5.5 days, s 201 (1:6) HIV RNA 7.4 days, GenScreen Plus p24/anti-HIV 17.8 days, PRISM anti-HIV 19.0 days, Tigris HBV DNA 20.6 days, s 201 (1:6) HBV DNA 22.6 days, Bio-Rad hepatitis B surface antigen (HBsAg) 37.8 days, and PRISM HBsAg 35.5 days.
|
19389212 |
2009 |
|
Hepatitis B
|
0.030 |
Biomarker
|
disease |
BEFREE |
For these samples, detection at the HBsAg assay cutoff (sample-to-cutoff ratio, 1.0) corresponded to 206 copies/mL HBV DNA for the HBsAg Prototype 1 assay and 329 copies/mL for the PRISM HBsAg assay.
|
22321072 |
2012 |
|
Hepatitis C
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Volunteer blood donations were screened, in parallel, for antibodies to hepatitis C virus (anti-HCV) and for human immunodeficiency virus (HIV)/HCV RNA using the Abbott PRISM HCV Chemiluminescent immunoassay (ChLIA) and the Chiron Procleix HIV-1/HCV RNA assays, respectively.
|
12823724 |
2003 |
|
Hepatitis C
|
0.030 |
Biomarker
|
disease |
BEFREE |
The results of this study indicate that PRISM ChLIA s/co ratios >2·00 with IB indeterminate results predict exposure to HCV, particularly in the presence of putative risk factors for HCV infection.
|
28850195 |
2017 |
|
Hepatitis C
|
0.030 |
Biomarker
|
disease |
BEFREE |
A semi-automated HCV extraction method was also implemented using the ABI PRISM 6100 Nucleic Acid PrepStation.
|
18551325 |
2008 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.020 |
Biomarker
|
disease |
BEFREE |
The mean IWPs were Tigris HIV RNA 5.5 days, s 201 (1:6) HIV RNA 7.4 days, GenScreen Plus p24/anti-HIV 17.8 days, PRISM anti-HIV 19.0 days, Tigris HBV DNA 20.6 days, s 201 (1:6) HBV DNA 22.6 days, Bio-Rad hepatitis B surface antigen (HBsAg) 37.8 days, and PRISM HBsAg 35.5 days.
|
19389212 |
2009 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.020 |
Biomarker
|
disease |
BEFREE |
Volunteer blood donations were screened, in parallel, for antibodies to hepatitis C virus (anti-HCV) and for human immunodeficiency virus (HIV)/HCV RNA using the Abbott PRISM HCV Chemiluminescent immunoassay (ChLIA) and the Chiron Procleix HIV-1/HCV RNA assays, respectively.
|
12823724 |
2003 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
This review represents the output of the collaborative group "PRISM", tasked with considering assay choices for assessment of attention and working memory in a transdiagnostic cohort of Alzheimer's disease and schizophrenia patients exhibiting symptomatic spectra of social withdrawal.
|
30399355 |
2019 |
|
Anxiety
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We explored the relationship of a visual measure of suffering, the PRISM-RII, with quality of life (QoL) and anxiety measures in IBS patients.
|
28744463 |
2017 |
|
Malignant neoplasm of thyroid
|
0.010 |
Biomarker
|
disease |
BEFREE |
The assessment tools included the following: (1) the PRISM-R2, yielding Self-Illness Separation (SIS) and Illness Perception Measure (IPM); (2) distress thermometer (DT), a measure of thyroid cancer-related distress; (3) posttraumatic growth inventory (PTGI); (4) 12-item Short-Form health survey (SF-12); and (5) the Supportive Care Needs Survey Short Form (SCNS-SF34).
|
29644472 |
2018 |
|
Hypertrophic Cardiomyopathy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The operating temperature of a commercially available capillary electrophoresis instrument (ABI PRISM 310) was expanded by installation of a cheap in-house designed cooling system, thereby allowing us to perform automated SSCP analysis at 14-45 degrees C. We have used the method for detection of point mutations associated with the inherited cardiac disorders long QT syndrome (LQTS) and hypertrophic cardiomyopathy (HCM).
|
10220146 |
1999 |
|
Intracranial Aneurysm
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We found that the suggestive IA locus at 5q23.2 in PRDM6 was significantly associated with SBP in individuals of European descent (p(FIN) = 3.01E-05, p(ICBP-GWAS) = 0.0007, p(ALL) = 8.13E-07).
|
22438818 |
2012 |
|
Delirium
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Children who were more seriously ill, such as those in a pediatric ICU (PICU) and those with a high Pediatric Risk of Mortality II (PRISM II) score, and children who were mechanically ventilated were at greater risk for development of delirium.
|
29543606 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Homogeneous groups of 70 patients with AITD, 70 with type 1 diabetes (T1D), 70 with both AITD and T1D (PGA), and 100 healthy controls were genotyped for the CTLA-4 CT60 and TNF-alpha-863 polymorphisms by minisequencing on an ABI PRISM-3100 genetic analyzer.
|
19530270 |
2009 |